GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Ending Cash Position

CSL (ASX:CSL) Ending Cash Position : A$2,474 Mil (As of Jun. 2024)


View and export this data going back to 1994. Start your Free Trial

What is CSL Ending Cash Position?

CSL's Ending Cash Position for the quarter that ended in Jun. 2024 was A$2,474 Mil.

CSL's quarterly Ending Cash Position declined from Jun. 2023 (A$2,248 Mil) to Dec. 2023 (A$1,510 Mil) but then increased from Dec. 2023 (A$1,510 Mil) to Jun. 2024 (A$2,474 Mil).

CSL's annual Ending Cash Position declined from Jun. 2022 (A$14,706 Mil) to Jun. 2023 (A$2,248 Mil) but then increased from Jun. 2023 (A$2,248 Mil) to Jun. 2024 (A$2,474 Mil).

CSL Ending Cash Position Historical Data

The historical data trend for CSL's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Ending Cash Position Chart

CSL Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,668.23 2,262.97 14,705.85 2,248.41 2,474.36

CSL Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,705.85 2,160.31 2,248.41 1,510.43 2,474.36

CSL Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

CSL's Ending Cash Position for the fiscal year that ended in Jun. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2272.554+201.804
=2,474

CSL's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1522.566+951.792
=2,474

CSL Ending Cash Position Related Terms

Thank you for viewing the detailed overview of CSL's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Ending Cash Position
Comparable Companies
ASX:TLX ASX:CU6 ASX:MSB ASX:NEU ASX:PYCDA ASX:OPT ASX:CUV ASX:BOT ASX:IMM ASX:IMU VRTX REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE UTHR
Traded in Other Exchanges
CSLLY:USA CMXHF:USA CSJA:Germany CSJ:Germany CSJ:Germany CSJ:Germany
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
Website
https://www.csl.com
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.